ARRT Radiography Exam Quiz: Manage Contrast Media Safely
13 questions · exam conditions
0:00
Manage Contrast Media SafelyQuestion 1 of 13

A patient scheduled for contrast CT reports taking the following medications: lisinopril, metformin, furosemide, and phenformin. Laboratory results show creatinine 1.8 mg/dL and eGFR 42 mL/min/1.73m². Which medication management approach is most critical for contrast safety?

Discontinue lisinopril 24 hours before contrast to prevent acute kidney injury
Continue all medications since eGFR is above 30 mL/min/1.73m² threshold
Temporarily discontinue furosemide to maintain adequate hydration before contrast
Hold both metformin and phenformin for 48 hours post-contrast due to lactic acidosis risk
← Back to quizzes

ARRT Radiography Exam Quiz

ARRT Radiography Exam Quiz: Manage Contrast Media Safely

Practice Manage Contrast Media Safely in ARRT Radiography Exam with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Manage Contrast Media Safely, giving you a quick way to practice the rules, question types, and explanations that matter most for ARRT Radiography Exam.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient scheduled for contrast CT reports taking the following medications: lisinopril, metformin, furosemide, and phenformin. Laboratory results show creatinine 1.8 mg/dL and eGFR 42 mL/min/1.73m². Which medication management approach is most critical for contrast safety?

  1. Discontinue lisinopril 24 hours before contrast to prevent acute kidney injury
  2. Continue all medications since eGFR is above 30 mL/min/1.73m² threshold
  3. Temporarily discontinue furosemide to maintain adequate hydration before contrast
  4. Hold both metformin and phenformin for 48 hours post-contrast due to lactic acidosis risk (correct answer)
Explanation: When evaluating medication safety before contrast CT, you must identify which drugs pose the highest risk for serious complications in patients with compromised kidney function. This patient's creatinine of 1.8 mg/dL and eGFR of 42 mL/min/1.73m² indicate moderate kidney impairment (Stage 3 CKD). The critical concern here is preventing contrast-induced nephropathy from triggering life-threatening lactic acidosis. Both metformin and phenformin are biguanide medications that can cause severe lactic acidosis if kidney function deteriorates further after contrast exposure. These medications are primarily eliminated by the kidneys, so any additional kidney damage from contrast could lead to dangerous drug accumulation. Current guidelines recommend holding biguanides for 48 hours post-contrast to allow kidney function assessment before resuming. Answer D correctly identifies this critical safety measure. Answer A is incorrect because lisinopril discontinuation isn't routinely required for contrast procedures, and 24 hours is an arbitrary timeframe. Answer B dangerously ignores the biguanide risk - while eGFR above 30 may be acceptable for contrast administration itself, it doesn't eliminate the lactic acidosis concern. Answer C misunderstands furosemide management; while hydration is important, temporarily holding a diuretic isn't the most critical intervention compared to preventing potentially fatal lactic acidosis. For radiography exams, remember that biguanide medications (metformin, phenformin) + contrast + kidney impairment = mandatory post-contrast hold to prevent lactic acidosis. This combination appears frequently on certification exams because it represents a serious, preventable complication.

Question 2

A technologist is reviewing premedication orders for a patient with a history of moderate contrast reaction (bronchospasm and urticaria) from a previous study. The orders specify: prednisone 50mg PO at 13, 7, and 1 hours before contrast, plus diphenhydramine 50mg PO 1 hour before. The patient arrives having taken only the 13-hour and 7-hour prednisone doses. What is the most appropriate action?

  1. Proceed immediately since two steroid doses provide adequate protection
  2. Substitute IV methylprednisolone 125mg and proceed with emergency medications available
  3. Cancel and reschedule with proper premedication timing for safety
  4. Delay examination 1 hour to complete the full premedication protocol as ordered (correct answer)
Explanation: When you encounter contrast premedication questions, think systematically about patient safety protocols and the importance of following established medical orders completely. The correct approach is D) Delay examination 1 hour to complete the full premedication protocol as ordered. This patient has a documented history of moderate contrast reaction requiring a specific three-dose steroid regimen plus antihistamine premedication. The protocol exists because all components work together to provide optimal protection. Since the patient has taken two of three prednisone doses, waiting one hour allows completion of the exact regimen the physician ordered, ensuring maximum safety while minimizing delay. A is incorrect because assuming "adequate protection" from partial premedication is dangerous practice. The three-dose regimen was specifically ordered based on this patient's reaction history, and incomplete protocols increase reaction risk. B substitutes a different medication and route without physician authorization. While IV methylprednisolone is sometimes used, you cannot independently change prescribed premedication protocols. This also doesn't address the missing antihistamine component. C represents unnecessary overcautiousness. Complete rescheduling wastes time and resources when the protocol can be completed with minimal delay. The patient has already taken most of the regimen correctly. Key strategy: On contrast-related questions, always prioritize patient safety while following medical orders exactly as written. Never assume partial premedication is "good enough" for patients with documented reaction histories. When protocols can be completed with reasonable delays, this is typically preferred over cancellation or unauthorized substitutions.

Question 3

During an IV contrast injection, a patient suddenly develops facial flushing, urticaria, and reports difficulty swallowing. Blood pressure drops from 130/80 to 90/60 mmHg. The technologist should take which immediate action sequence?

  1. Stop injection, call for help, administer epinephrine 0.1mg IV, establish additional IV access (correct answer)
  2. Continue injection at slower rate, give diphenhydramine 50mg IV, monitor vitals every 5 minutes
  3. Stop injection, position patient supine, administer oxygen, give methylprednisolone 125mg IV
  4. Discontinue injection, keep patient upright, give albuterol treatment, document reaction severity
Explanation: This presentation indicates anaphylaxis (urticaria, angioedema with dysphagia, hypotension). Immediate epinephrine administration is critical, along with stopping the injection and calling for help. Choice B is dangerous as it continues the injection. Choice C uses corticosteroids instead of epinephrine as first-line treatment. Choice D treats bronchospasm but misses the anaphylactic nature and keeps patient upright instead of supine for hypotension.

Question 4

A technologist is preparing to administer barium sulfate for an upper GI series when the patient mentions they may have a bowel perforation. The patient's requisition indicates 'rule out gastric perforation.' What is the most appropriate contrast management decision?

  1. Proceed with thin barium preparation using careful fluoroscopic monitoring and immediate imaging to minimize contrast exposure time
  2. Substitute water-soluble iodinated contrast and notify the radiologist of the perforation concern before beginning the examination (correct answer)
  3. Use air contrast technique exclusively without any liquid contrast material to avoid complications while maintaining diagnostic quality
  4. Continue with standard barium protocol since the perforation is only suspected and barium provides superior diagnostic imaging quality
Explanation: Suspected bowel perforation is an absolute contraindication to barium use due to risk of barium peritonitis, which can be fatal. Water-soluble contrast (gastrografin) should be used instead, though it may cause pulmonary edema if aspirated. Choice A ignores the contraindication. Choice C won't provide adequate mucosal detail for perforation assessment. Choice D is dangerous as barium extravasation into peritoneum causes severe inflammatory reaction.

Question 5

During contrast injection for CT angiography, the technologist notices contrast extravasation at the IV site with moderate swelling and patient complaints of burning pain. The injection is immediately stopped with approximately 75 mL of contrast extravasated. What is the most appropriate immediate management sequence?

  1. Apply warm compresses, elevate the extremity, notify physician, and document the volume extravasated with photographic evidence if possible
  2. Remove the IV catheter immediately, apply ice packs, administer analgesics, and schedule surgical consultation within 6 hours
  3. Leave IV in place for potential antidote administration, apply cold therapy, elevate extremity, and monitor for compartment syndrome signs (correct answer)
  4. Massage the area to disperse contrast, apply pressure dressing, administer antihistamines, and reassure patient that symptoms will resolve
Explanation: For large-volume contrast extravasation (>75 mL is considered significant), the IV should remain in place briefly in case antidote or aspiration is needed. Cold therapy reduces inflammation, elevation promotes drainage, and compartment syndrome monitoring is crucial with large volumes. Choice A uses heat which increases inflammation. Choice B removes IV too quickly and suggests routine surgery. Choice D includes massage which can worsen tissue damage and pressure dressing which could compromise circulation.

Question 6

A patient develops bradycardia (heart rate 45 bpm), hypotension (BP 85/50), and reports severe nausea immediately after rapid IV contrast injection. The patient appears diaphoretic but has no respiratory distress or skin changes. This reaction pattern is most consistent with:

  1. Anaphylactoid reaction requiring immediate epinephrine administration and aggressive fluid resuscitation with continuous cardiac monitoring
  2. Vasovagal response necessitating supine positioning, IV fluids, and possible atropine administration if bradycardia persists (correct answer)
  3. Contrast-induced cardiotoxicity requiring emergency cardiology consultation and immediate beta-blocker therapy discontinuation
  4. Osmotic shock from contrast load demanding rapid volume expansion with crystalloid solutions and electrolyte monitoring
Explanation: The combination of bradycardia, hypotension, nausea, and diaphoresis without respiratory or dermatologic symptoms indicates vasovagal response, which can occur with contrast injection anxiety or rapid injection rates. Treatment focuses on positioning and fluid support, with atropine for persistent bradycardia. Choice A misidentifies this as anaphylaxis. Choice C incorrectly suggests cardiac toxicity. Choice D describes volume effects but misses the vagal component.

Question 7

An interventional radiologist is planning lower extremity angiography on a patient with a severe iodinated contrast allergy and impaired renal function (eGFR 28 mL/min/1.73m²). The radiologist mentions carbon dioxide (CO₂) as an alternative intravascular contrast agent. Which of the following MOST accurately describes the appropriate use of CO₂ as a vascular contrast agent?

  1. CO₂ is used as an oral contrast agent for CT colonography; it is never used for intravascular procedures because gas in blood vessels always causes fatal embolism
  2. CO₂ can substitute for iodinated contrast in any intravascular procedure, including coronary and cerebral angiography, and provides equivalent diagnostic image quality for all vessel types and locations
  3. CO₂ is approved only for research protocols in the United States; its use in clinical intravascular procedures is experimental and not part of routine interventional practice
  4. CO₂ is suitable for angiography below the diaphragm in patients with contrast allergies and renal impairment, but contraindicated above the diaphragm due to risk of gas embolism. (correct answer)
Explanation: How to get the right answer: CO₂ is a clinically established intravascular contrast agent specifically used when iodinated contrast is contraindicated or high-risk. It is non-allergenic, addressing the severe allergy in this patient, and non-nephrotoxic, addressing the impaired renal function. When injected intravascularly, CO₂ displaces blood and provides negative contrast on digital subtraction angiography. It is appropriate for vessels below the diaphragm, including the abdominal aorta, iliac arteries, renal arteries, mesenteric arteries, and peripheral lower extremity vessels. The absolute contraindication to CO₂ above the diaphragm stems from the risk of gas accumulation in coronary or cerebral vessels: CO₂ dissolves more slowly in smaller vessels, and coronary or cerebrovascular gas lock can cause myocardial infarction or stroke. Dedicated CO₂ delivery systems with non-return valves are required to prevent accidental injection of room air, which would be far more dangerous than CO₂. Why the other answers are wrong: Choice A confuses intravascular CO₂ with the CO₂ insufflation used for bowel distension in CT colonography; intravascular CO₂ angiography is an entirely separate, clinically established application with a well-documented safety and efficacy profile in appropriate vessel territories. Choice B claims CO₂ can substitute for iodinated contrast in any vessel including coronary and cerebral arteries; above-diaphragm CO₂ injection is absolutely contraindicated due to coronary and cerebrovascular gas embolism risk. Choice C characterizes intravascular CO₂ as experimental in the United States; it is a recognized clinical contrast alternative routinely used in interventional radiology practice, not an investigational agent restricted to research protocols. Big idea to remember: CO₂ intravascular contrast is non-nephrotoxic and non-allergenic, making it appropriate for below-diaphragm angiography; it is absolutely contraindicated above the diaphragm because CO₂ gas in coronary or cerebral vessels can produce gas lock with potentially fatal ischemic consequences.

Question 8

A patient with suspected esophageal perforation from a Boerhaave syndrome event is referred for an esophagram contrast study. Which of the following MOST accurately describes the appropriate contrast selection and important caveats?

  1. Barium sulfate is preferred for Boerhaave syndrome because its superior mucosal coating helps detect small perforations that might be missed by water-soluble contrast
  2. Both barium and water-soluble contrast are clinically equivalent for esophageal perforation studies; the choice depends solely on which agent is available in the department
  3. Use water-soluble iodinated contrast initially for suspected esophageal perforation; avoid high-osmolality agents if aspiration risk exists, opting for dilute iohexol instead. (correct answer)
  4. Neither barium nor iodinated contrast should be used for suspected esophageal perforation; CT without contrast is the appropriate first-line study for all suspected perforations
Explanation: How to get the right answer: Barium sulfate is absolutely contraindicated when esophageal perforation is suspected because barium entering the mediastinum or pleural space causes an intense granulomatous inflammatory reaction called barium mediastinitis, which dramatically worsens outcomes compared to water-soluble agent leakage. Water-soluble iodinated contrast agents are absorbed from the mediastinum and pleural space without causing significant chemical reaction, making them the correct first choice. A critical caveat applies: high-osmolality agents like undiluted Gastrografin (diatrizoate meglumine) draw fluid into the airways if aspirated and can cause fatal chemical pneumonitis or pulmonary edema. Patients with esophageal disease often have impaired swallowing coordination and are at risk for aspiration, so when aspiration risk is present or uncertain, dilute iohexol (with substantially lower osmolality) is much safer. When the water-soluble study is negative and clinical suspicion remains high, some radiologists follow with dilute barium to capitalize on its superior mucosal sensitivity. Why the other answers are wrong: Choice A advocates barium for Boerhaave syndrome; barium mediastinitis after perforation carries extremely high morbidity, and the diagnostic advantage of superior mucosal coating does not justify this risk; barium is specifically contraindicated whenever esophageal perforation is suspected. Choice B claims the agents are clinically equivalent for this indication; barium causes chemical mediastinitis while water-soluble agents do not, making them emphatically non-equivalent when perforation cannot be excluded. Choice D proposes CT without contrast as the only appropriate study; while CT can demonstrate pneumomediastinum and pleural effusion, a contrast esophagram specifically evaluates the mucosal defect and visible contrast leak, providing complementary diagnostic information that CT alone cannot replicate. Big idea to remember: For suspected esophageal perforation, use water-soluble iodinated contrast first (barium causes barium mediastinitis); when aspiration risk is present, use dilute iohexol rather than undiluted high-osmolality Gastrografin, which can cause fatal pulmonary edema if aspirated.

Question 9

A radiographer is about to administer iodinated IV contrast for an outpatient CT when they notice the patient's wristband reads "JOHNSON, DAVID" while the CT order reads "JOHNSON, DANIEL." The patient explains: "That happens all the time because my brother and I have similar names and we're both in the system." Which of the following MOST accurately describes the correct response?

  1. Accept the patient's explanation and proceed; this type of naming confusion is common in healthcare systems and the patient's verbal explanation resolves the discrepancy
  2. Verify the patient's identity using a second identifier, like date of birth, before proceeding with contrast administration to ensure accurate patient identification. (correct answer)
  3. Ask the patient to review the images and verify which study is theirs; patient self-identification resolves ID discrepancies
  4. Proceed with the scan but add an electronic note flagging the name discrepancy for the radiologist to resolve during interpretation
Explanation: How to get the right answer: Two-identifier verification (name plus date of birth, or name plus medical record number) is required before contrast administration. A discrepancy in the patient's first name cannot be resolved by verbal explanation, particularly when that explanation specifically introduces the possibility of a similarly named sibling in the same healthcare system. The patient's statement actually increases the identification risk rather than resolving it: the person being scanned might be the brother. Both identifiers must be confirmed against the specific order before proceeding. Date of birth confirmed against the order, or the MRN on the wristband matched to the MRN on the order, are the appropriate verification steps. Only when both identifiers unambiguously match the order should contrast be administered. When any doubt remains, the ordering physician must be contacted before proceeding with a pharmacologically active agent. Why the other answers are wrong: Choice A accepts the verbal explanation as resolving the discrepancy; the patient's mention of a sibling in the same system heightens rather than resolves the identification concern, and a plausible verbal explanation cannot substitute for documented identifier confirmation. Choice C uses patient self-identification via image review; patients are not trained to interpret medical images; identification must use formal identifiers such as date of birth and medical record number, not patient review of radiographic anatomy. Choice D releases with a radiologist flag; releasing a known potentially mislabeled study into the system creates immediate patient safety risk and must not occur until identification is confirmed. Big idea to remember: Any patient identification discrepancy must be resolved through confirmation of a second independent identifier (date of birth or MRN matched to the order) before contrast is administered; a patient's verbal explanation that introduces a sibling in the same system increases rather than resolves the identification risk.

Question 10

A neuroradiologist is counseling a patient who has received multiple gadolinium-enhanced brain MRIs over 6 years for MS monitoring and who has read about "gadolinium in the brain." Which of the following MOST accurately describes the current understanding of gadolinium brain deposition?

  1. Gadolinium retention in the brain is not supported by published research; multiple large studies have confirmed that all gadolinium is fully excreted within 72 hours of injection regardless of agent type or dose
  2. Brain gadolinium deposition causes measurable cognitive decline after three or more gadolinium-enhanced MRI studies; the FDA has recommended limiting each patient to no more than three lifetime gadolinium injections
  3. Gadolinium deposits in the brain are more pronounced with linear agents than macrocyclic ones; clinical significance remains unclear, but macrocyclic agents are preferred to minimize deposition in patients requiring multiple doses. (correct answer)
  4. Brain gadolinium retention causes NSF in patients with normal renal function; all patients with gadolinium deposits in the brain will eventually develop clinically apparent NSF regardless of renal function
Explanation: How to get the right answer: Multiple independent studies confirmed that T1 hyperintensity develops in the dentate nucleus and globus pallidus of patients who received multiple GBCA injections, even with normal renal function. Post-mortem brain tissue analysis confirmed actual gadolinium deposits in these regions. The phenomenon is significantly more pronounced with linear GBCAs such as gadodiamide and gadopentetate dimeglumine than with macrocyclic agents, consistent with the greater molecular stability and lower free Gd³⁺ release from macrocyclic structures. The critical current uncertainty is clinical significance: no definitive causal relationship between brain gadolinium deposits and neurological symptoms or cognitive decline has been established in patients with normal renal function. This distinguishes brain deposition from NSF, which is a renal-mediated condition requiring severely impaired clearance. The FDA updated GBCA product labeling to acknowledge retention, and current guidance is to prefer macrocyclic agents for patients likely to receive multiple lifetime GBCA doses. Why the other answers are wrong: Choice A denies documented gadolinium retention in the brain; this finding is well established, supported by both MRI signal changes on T1-weighted unenhanced images and post-mortem tissue analysis confirming actual gadolinium deposits in the dentate nucleus and globus pallidus. Choice B cites established cognitive decline and a three-injection FDA limit; no causal cognitive decline has been confirmed in neurologically normal patients and no FDA recommendation exists limiting lifetime gadolinium injections to three. Choice D links brain deposition to NSF development in normal renal function patients; NSF is a renal-mediated condition requiring significantly impaired renal clearance for gadolinium to accumulate to tissue-depositing levels in skin and internal organs; brain deposition in patients with normal renal function does not produce NSF. Big idea to remember: Gadolinium brain deposition (T1 signal changes in dentate nucleus and globus pallidus) is documented but of uncertain clinical significance in patients with normal renal function; it is more pronounced with linear than macrocyclic agents; macrocyclic agents are preferred for patients requiring multiple lifetime GBCA doses to minimize deposition.

Question 11

A patient with multiple myeloma is referred for a contrast-enhanced CT for staging purposes. Which of the following MOST accurately describes the contrast-related risk specific to multiple myeloma patients and the appropriate management?

  1. Multiple myeloma is not a risk factor for any contrast-related complication; patients with myeloma may receive iodinated contrast without any special consideration
  2. Patients with multiple myeloma and renal impairment are at risk for contrast-induced nephropathy; ensure adequate hydration and assess renal function before administering contrast. (correct answer)
  3. Multiple myeloma requires mandatory pre-medication with corticosteroids because monoclonal immunoglobulins interact directly with iodinated contrast to trigger anaphylaxis
  4. Iodinated contrast is absolutely contraindicated in all multiple myeloma patients because contrast permanently binds to monoclonal proteins and causes fatal precipitation in the systemic circulation
Explanation: How to get the right answer: Multiple myeloma cells produce abnormal immunoglobulins including monoclonal light chains (Bence Jones proteins) that are freely filtered at the glomerulus and enter the tubular lumen. These light chains can precipitate in the distal tubule and collecting duct when tubular flow rate is reduced or protein concentration increases, a condition called cast nephropathy. Iodinated contrast can promote this event through two mechanisms: the osmotic diuresis produced by contrast followed by relative dehydration reduces tubular flow and concentrates tubular proteins, and contrast may directly increase tubular protein aggregation. The risk is most significant in patients with concurrent renal impairment and myeloma. Adequate hydration before and after contrast is the primary protective measure because it maintains tubular flow rate and reduces tubular protein concentration. Critically, Bence Jones protein precipitation is not an allergic or anaphylaxis mechanism, so corticosteroid pre-medication for allergy prevention is not indicated for this specific risk. Contrast is not absolutely contraindicated in myeloma patients who have adequate renal function and are well hydrated. Why the other answers are wrong: Choice A dismisses myeloma as a risk factor entirely; the Bence Jones protein tubular precipitation mechanism is a recognized contrast risk in myeloma patients with renal impairment, and proceeding without any assessment ignores an actionable safety consideration. Choice C mandates corticosteroid pre-medication on the basis of an anaphylaxis mechanism; the myeloma-contrast risk is a tubular precipitation risk driven by Bence Jones proteins, not an IgE-mediated or anaphylactoid mechanism, and corticosteroid pre-medication for allergy prevention does not address this specific risk. Choice D absolutely contraindicates contrast in all myeloma patients; contrast is conditionally safe in myeloma patients with adequate renal function and proper hydration, and the staging examination may have important clinical value that outweighs the manageable risk. Big idea to remember: Multiple myeloma patients are at elevated CIN risk because Bence Jones proteins can precipitate in renal tubules when contrast reduces tubular flow (cast nephropathy); this is a tubular precipitation mechanism, not anaphylaxis, so corticosteroid pre-medication is not indicated; adequate IV hydration is the primary protective measure.

Question 12

A 58-year-old patient with stage 4 chronic kidney disease (eGFR 22 mL/min/1.73m²) requires an MRI with contrast for evaluation of a brain lesion. The radiologist is considering gadolinium-based contrast agent (GBCA) administration. Which of the following MOST accurately describes the specific risk and appropriate management?

  1. Select a macrocyclic GBCA due to lower NSF risk in patients with eGFR below 30 mL/min/1.73m²; use the minimum effective dose and ensure informed consent addresses NSF risk. (correct answer)
  2. Gadolinium is exclusively metabolized by the liver and has no renal clearance requirements; NSF risk applies only to patients who are actively on dialysis, not those with moderate or severe chronic kidney disease
  3. All gadolinium agents carry identical NSF risk regardless of molecular structure; the only safe approach for this patient is to perform the MRI without contrast
  4. NSF risk applies only to ionic gadolinium agents; non-ionic gadolinium formulations are safe to administer in any degree of renal impairment without special precautions
Explanation: How to get the right answer: NSF (nephrogenic systemic fibrosis) is a fibrotic condition of the skin and internal organs linked to free gadolinium ions deposited in tissue. It occurs almost exclusively in patients with severe renal impairment (eGFR below 30 mL/min/1.73m²) or on dialysis, where reduced gadolinium clearance prolongs systemic exposure. An eGFR of 22 is well within this high-risk range. The critical management factor is GBCA selection based on molecular structure: macrocyclic agents such as gadobutrol, gadoterate, and gadoteridol have a cage-like structure that binds gadolinium much more tightly than linear agents, releasing significantly less free Gd³⁺ and conferring substantially lower NSF risk. Several linear GBCAs have been restricted or withdrawn by the FDA due to NSF risk in renally impaired patients. For this patient, a macrocyclic agent at the minimum effective dose is the preferred approach following thorough risk-benefit documentation and informed consent that specifically addresses NSF risk. Why the other answers are wrong: Choice B claims gadolinium is liver-metabolized and that NSF risk applies only to dialysis patients; gadolinium is renally cleared, not hepatically metabolized, and NSF risk begins at eGFR below 30 mL/min/1.73m², not only at dialysis dependence. Choice C recommends avoiding all GBCAs on the basis of identical risk across agents; this disregards the well-established and clinically important difference between macrocyclic and linear agents, which is the primary basis for current safe GBCA use in renally impaired patients when contrast is essential. Choice D claims non-ionic agents are safe in any degree of renal impairment; the ionic/non-ionic classification is different from and less relevant than the macrocyclic/linear classification for NSF risk, and non-ionic linear agents still carry elevated NSF risk. Big idea to remember: NSF risk from GBCAs is highest at eGFR below 30 mL/min/1.73m²; the key risk stratifier is molecular structure (macrocyclic vs. linear, not ionic vs. non-ionic), with macrocyclic agents conferring substantially lower NSF risk due to their tightly bound gadolinium cage structure.

Question 13

A patient received iodinated IV contrast for a CT scan and returns to their physician two weeks later for a thyroid scan and planned radioiodine (¹³¹I) therapy for hyperthyroidism. The nuclear medicine physician asks whether the recent contrast administration affects these procedures. Which of the following MOST accurately describes the effect of iodinated contrast on thyroid nuclear medicine procedures?

  1. Iodinated contrast temporarily reduces radioiodine uptake due to iodine saturation, affecting thyroid scans and therapy. Procedures should be delayed for 4 to 8 weeks post-contrast to ensure accurate results and effective treatment. (correct answer)
  2. Iodinated contrast has no effect on thyroid nuclear medicine procedures; the contrast iodine is biologically inactive and does not interact with thyroid iodine metabolism or the radioiodine uptake mechanism
  3. Iodinated contrast permanently suppresses radioiodine uptake; any patient who received contrast will never be eligible for radioiodine therapy
  4. The effect of contrast on thyroid function tests (TSH, free T4) is significant; serum TSH levels become undetectable for 6 months after any iodinated contrast injection, making hyperthyroidism impossible to monitor
Explanation: How to get the right answer: Each dose of iodinated IV contrast contains 10 to 40 grams of organic iodine. As the body metabolizes the contrast agent, free inorganic iodide is released into the circulation. The thyroid gland uses an iodide trapping mechanism (sodium-iodide symporter) to concentrate iodine for thyroid hormone synthesis, and this same mechanism takes up radioiodine (¹³¹I) for diagnostic scans and therapeutic ablation. When plasma iodide levels are massively elevated by contrast metabolism, the thyroid's iodide transporter becomes saturated through the Wolff-Chaikoff effect: the gland cannot significantly increase its uptake of the small additional tracer dose of radioiodine. Diagnostic thyroid scans show falsely suppressed uptake values, and radioiodine therapy is markedly less effective because the therapeutic ¹³¹I competes with far more abundant stable iodide for transporter binding sites. The waiting period for iodide clearance is typically 4 to 8 weeks for standard contrast doses, with some protocols extending the wait to 2 to 3 months for hyperthyroid patients where iodine handling may differ. Why the other answers are wrong: Choice B claims contrast iodine is biologically inactive and has no effect on thyroid nuclear medicine; the massive iodine load from contrast demonstrably suppresses thyroid radioiodine uptake through the Wolff-Chaikoff mechanism, and this is a well-documented, clinically actionable interaction that affects nuclear medicine scheduling. Choice C claims permanent suppression of radioiodine uptake; the effect is temporary and reversible, typically lasting 4 to 8 weeks as excess iodide is renally cleared, after which radioiodine therapy eligibility is fully restored. Choice D claims serum TSH becomes undetectable for 6 months; serum TSH, free T4, and free T3 blood assays are not significantly affected by contrast iodine loading; the interference is specifically with radioiodine uptake in nuclear medicine procedures that require functional iodide trapping, not with routine serum thyroid hormone measurements. Big idea to remember: Iodinated contrast delivers a massive iodine load that saturates thyroid iodide uptake pathways (Wolff-Chaikoff effect), producing falsely suppressed radioiodine uptake and reduced radioiodine therapy effectiveness; thyroid scans and ¹³¹I therapy must be deferred at least 4 to 8 weeks after contrast administration.